CLL Research

Fixed Duration Ibrutinib‐Venetoclax, a Redefinition of the CLL Treatment Landscape (2025)
Journal Article
Molica, S., & Allsup, D. (2025). Fixed Duration Ibrutinib‐Venetoclax, a Redefinition of the CLL Treatment Landscape. Hematological Oncology, 43(3), Article e70088. https://doi.org/10.1002/hon.70088

The fixed-duration combination of ibrutinib and venetoclax (IV) has emerged as a highly effective therapeutic strategy for treating chronic lymphocytic leukemia (CLL), marking a significant shift in the treatment paradigm for this disease. Preclinica... Read More about Fixed Duration Ibrutinib‐Venetoclax, a Redefinition of the CLL Treatment Landscape.

Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors (2025)
Journal Article
Molica, S., & Allsup, D. (2025). Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors. Cancers, 17(1), Article 119. https://doi.org/10.3390/cancers17010119

Chronic lymphocytic leukemia (CLL) treatment has evolved from traditional chemotherapy to targeted therapies, such as Bruton tyrosine kinase (BTK) and BCL-2 inhibitors with significant improvements in survival rates and a transformation of CLL into a... Read More about Chronic Lymphocytic Leukemia Care and Beyond: Navigating the Needs of Long-Term Survivors.